The offering also includes pre-funded warrants for 833,333 shares, priced at the same $6 rate for investors opting out of immediate common stock ownership. To manage the sale, the company tapped a syndicate of heavyweights, including Jefferies, Goldman Sachs, Piper Sandler, and Cantor, to serve as joint book-running managers. The deal is slated to close on or about Friday.
In section Market Quotes
Taysha Gene Therapies Shares Slide on $200 Million Stock Offering
A 9.8% drop in premarket trading greeted Taysha Gene Therapies on Thursday after the biotechnology firm finalized the pricing for a $200 million public offering. The company is diluting its existing equity base to raise capital, selling 32.5 million common shares at $6 apiece to bolster its financial runway.
Despite the immediate market reaction, the company remains in a strong position relative to its recent performance. Before this morning's slide to $6.26, the stock had climbed approximately 25% since the start of the year. Underwriters maintain a 30-day window to purchase an additional 5 million shares, a provision that could further adjust the total capital raised depending on market appetite.
Comments (0)
No comments yet. Be the first!